13.51
price up icon0.37%   0.05
after-market Dopo l'orario di chiusura: 13.51
loading
Precedente Chiudi:
$13.46
Aprire:
$13.52
Volume 24 ore:
357.41K
Relative Volume:
0.80
Capitalizzazione di mercato:
$939.98M
Reddito:
$62.71M
Utile/perdita netta:
$-112.51M
Rapporto P/E:
-8.947
EPS:
-1.51
Flusso di cassa netto:
$-96.01M
1 W Prestazione:
-5.66%
1M Prestazione:
+8.34%
6M Prestazione:
-7.53%
1 anno Prestazione:
+27.45%
Intervallo 1D:
Value
$13.03
$13.58
Intervallo di 1 settimana:
Value
$13.03
$14.46
Portata 52W:
Value
$9.03
$17.70

Zymeworks Inc. Stock (ZYME) Company Profile

Name
Nome
Zymeworks Inc.
Name
Telefono
604-678-1388
Name
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Name
Dipendente
170
Name
Cinguettio
@ZymeworksInc
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
ZYME's Discussions on Twitter

Confronta ZYME con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
ZYME
Zymeworks Inc.
13.51 1.01B 62.71M -112.51M -96.01M -1.51
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
468.41 118.34B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
558.14 60.31B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
330.55 42.35B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
598.79 36.43B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
305.74 31.87B 3.81B -644.79M -669.77M -6.24

Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-20 Iniziato TD Cowen Buy
2024-12-16 Aggiornamento JP Morgan Neutral → Overweight
2024-11-07 Aggiornamento Leerink Partners Market Perform → Outperform
2024-11-01 Downgrade Wells Fargo Overweight → Equal Weight
2023-03-21 Ripresa Wells Fargo Overweight
2023-01-04 Reiterato H.C. Wainwright Neutral
2022-12-20 Aggiornamento Jefferies Hold → Buy
2022-11-01 Downgrade H.C. Wainwright Buy → Neutral
2022-10-21 Downgrade SVB Leerink Outperform → Mkt Perform
2022-10-04 Ripresa Wells Fargo Overweight
2022-05-05 Aggiornamento Guggenheim Neutral → Buy
2022-03-15 Iniziato Evercore ISI Outperform
2021-12-10 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-11-17 Ripresa Guggenheim Neutral
2021-10-07 Iniziato Jefferies Hold
2021-03-31 Iniziato Credit Suisse Outperform
2021-02-25 Downgrade SVB Leerink Outperform → Mkt Perform
2021-02-08 Ripresa H.C. Wainwright Buy
2021-01-25 Downgrade Citigroup Buy → Neutral
2020-09-29 Ripresa JP Morgan Neutral
2020-08-06 Iniziato SVB Leerink Outperform
2020-01-10 Iniziato Wolfe Research Outperform
2019-12-09 Iniziato JP Morgan Neutral
2019-11-25 Iniziato H.C. Wainwright Buy
2019-11-20 Iniziato Guggenheim Buy
2019-09-30 Aggiornamento Raymond James Outperform → Strong Buy
2019-08-30 Iniziato Stifel Buy
2019-07-18 Iniziato Deutsche Bank Buy
2018-05-11 Aggiornamento Barclays Underweight → Equal Weight
2018-03-19 Iniziato Raymond James Outperform
Mostra tutto

Zymeworks Inc. Borsa (ZYME) Ultime notizie

pulisher
Jul 29, 2025

Analyzing Zymeworks Inc. with risk reward ratio chartsFree Daily Top Performing Stock Insights - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

How to read the order book for Zymeworks Inc.Entry Signal Generator with Risk Metrics - Newser

Jul 29, 2025
pulisher
Jul 29, 2025

Zymeworks' IND for liver cancer antibody-drug conjugate given FDA clearance - MSN

Jul 29, 2025
pulisher
Jul 29, 2025

How did ZYME's Q1 2025 EPS forecast compare to past trends? - AInvest

Jul 29, 2025
pulisher
Jul 29, 2025

What factors could impact ZYME's future EPS growth? - AInvest

Jul 29, 2025
pulisher
Jul 28, 2025

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate - wahanariau.com

Jul 28, 2025
pulisher
Jul 28, 2025

Zymeworks’ second ADC with TOPO1 inhibitor payload to enter clinic in US - BioWorld MedTech

Jul 28, 2025
pulisher
Jul 28, 2025

Zymeworks’ ZW251 Receives FDA Clearance for Clinical Trials in Liver Cancer - TipRanks

Jul 28, 2025
pulisher
Jul 28, 2025

FDA clears Zymeworks’ IND for liver cancer drug candidate ZW251 By Investing.com - Investing.com South Africa

Jul 28, 2025
pulisher
Jul 28, 2025

Zymeworks Inc. Advances ZW251 into Clinical Development for Hepatocellular Carcinoma Following IND Clearance from FDA - Quiver Quantitative

Jul 28, 2025
pulisher
Jul 28, 2025

FDA Green Lights Revolutionary First-in-Class Liver Cancer Drug: Zymeworks Advances New Treatment - Stock Titan

Jul 28, 2025
pulisher
Jul 28, 2025

When is Zymeworks Inc. stock expected to show significant growthDiscover high-impact stocks for growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

What catalysts could drive Zymeworks Inc. stock higher in 2025Explosive trading growth - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How does Zymeworks Inc. compare to its industry peersOutstanding trading profits - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 28, 2025

How volatile is Zymeworks Inc. stock compared to the marketExponential return rates - jammulinksnews.com

Jul 28, 2025
pulisher
Jul 27, 2025

Does Zymeworks Inc. stock perform well during market downturnsCapitalize on fast-growing stocks today - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What are analysts’ price targets for Zymeworks Inc. in the next 12 monthsFree Stock Index Interpretation - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 27, 2025

What is Zymeworks Inc. company’s growth strategyGame-changing returns - jammulinksnews.com

Jul 27, 2025
pulisher
Jul 24, 2025

Will Zymeworks Inc. stock benefit from AI tech trendsFree Advanced Stock Screener Access - jammulinksnews.com

Jul 24, 2025
pulisher
Jul 23, 2025

What analysts say about Zymeworks Inc. stockRapid wealth multiplication - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Zymeworks Inc.'s (NASDAQ:ZYME) Shareholders Might Be Looking For Exit - 富途牛牛

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Zymeworks Inc. stock priceFree Market Dynamics Reports - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Is Zymeworks Inc. a good long term investmentPowerful growth strategies - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 23, 2025

Zymeworks Inc. (NYSE:ZYME) Shares Sold by Arizona State Retirement System - Defense World

Jul 23, 2025
pulisher
Jul 22, 2025

Zymeworks Announces Pricing of $100.0 Million Public Offering - Finance Monthly

Jul 22, 2025
pulisher
Jul 22, 2025

Zymeworks Inc. Stock Analysis and ForecastTremendous gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Teacher Retirement System of Texas Cuts Stock Position in Zymeworks Inc. (NYSE:ZYME) - Defense World

Jul 21, 2025
pulisher
Jul 19, 2025

Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains? - MSN

Jul 19, 2025
pulisher
Jul 18, 2025

Zymeworks to Announce Q2 2025 Financials and Engage in Investor Conferences - The Globe and Mail

Jul 18, 2025
pulisher
Jul 17, 2025

Zymeworks to Report Second Quarter 2025 Financial Results and Ho - GuruFocus

Jul 17, 2025
pulisher
Jul 17, 2025

Zymeworks Inc. to Release Second Quarter 2025 Financial Results on August 7, 2025 - Nasdaq

Jul 17, 2025

Zymeworks Inc. Azioni (ZYME) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$77.38
price up icon 10.28%
$37.27
price up icon 0.57%
$105.00
price up icon 3.19%
$26.74
price down icon 2.59%
$111.48
price down icon 1.16%
biotechnology ONC
$305.74
price up icon 3.81%
Capitalizzazione:     |  Volume (24 ore):